EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Utero Gene Therapies Using CRISPR-Cas9 Technology: A Narrative Review of Current Research and Translational Perspectives

Wiktoria Oczkowska, Aleksandra K. Pelczar, Kinga Głodek, Żaneta Kimber-Trojnar

International Journal of Molecular Sciences · 19.11.2026 · 27 (22) · 10388

DOI: 10.3390/ijms272210388 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.11.2026. Verfasst von Wiktoria Oczkowska und 3 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene therapy has emerged as a promising approach for the treatment and prevention of genetic disorders through targeted modification of cellular DNA. The clustered regularly interspaced short palindromic repeats-CRISPR-associated protein 9 (CRISPR-Cas9) system, in particular, has enabled precise correction of disease-causing mutations. Recently, increasing interest has been directed toward in utero gene therapy, which offers a unique therapeutic window to prevent irreversible pathological changes before birth. This narrative review explores the current preclinical landscape of in utero CRISPR-Cas9-mediated genome editing. A literature search was conducted using PubMed/MEDLINE and Google Scholar databases to identify relevant studies, focusing primarily on delivery strategies, temporal considerations, therapeutic efficacy, and safety outcomes. Preclinical evidence demonstrates that prenatal delivery of CRISPR-Cas9 components in animal models can achieve durable genome editing in multiple fetal tissues, leading to phenotypic improvements in metabolic and early-onset lethal disorders. However, significant challenges remain, including off-target effects, mosaicism, maternal–fetal immune interactions, and the risk of unintended germline transmission. Ultimately, while in utero CRISPR-Cas9 gene therapy holds substantial therapeutic potential for severe congenital pathologies, rigorous safety evaluation, delivery optimization, and resolution of ethical and regulatory dilemmas are strictly required before clinical translation can be considered.

Zitieren

APA

Oczkowska, W., Pelczar, A. K., Głodek, K., & Kimber-Trojnar, Ż. (2026). In Utero Gene Therapies Using CRISPR-Cas9 Technology: A Narrative Review of Current Research and Translational Perspectives. International Journal of Molecular Sciences, 27(22), 10388. https://doi.org/10.3390/ijms272210388

Vancouver

Oczkowska W, Pelczar AK, Głodek K, Kimber-Trojnar Ż. In Utero Gene Therapies Using CRISPR-Cas9 Technology: A Narrative Review of Current Research and Translational Perspectives. International Journal of Molecular Sciences. 2026;27(22):10388. doi:10.3390/ijms272210388

BibTeX
@article{Oczkowska2026,
  author = {Oczkowska, Wiktoria and Pelczar, Aleksandra K. and Głodek, Kinga and Kimber-Trojnar, Żaneta},
  title = {In Utero Gene Therapies Using CRISPR-Cas9 Technology: A Narrative Review of Current Research and Translational Perspectives},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {22},
  pages = {10388},
  doi = {10.3390/ijms272210388}
}
Kostenlos starten →